CytoSorbents Investor Relations
CytoSorbents is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, with more than 300,000 CytoSorb® devices sold in more than 70 countries to date, and seeking U.S. FDA market authorization for an investigational product, DrugSorb-ATR®, to remove blood thinning drugs.
Featured News
CytoSorbents
Press Release
CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement
PRINCETON, N.J., Sept. 23, 2026 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has regained compliance with the Nasdaq Stock Market’s minimum bid price requirement of $1.00 per share. On September 22, 2026, CytoSorbents received ... CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement
CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference
PRINCETON, N.J., Sept. 10, 2026 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, is pleased to announce its participation at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14–16, 2026, in New York City. Dr. ... CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference
CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
Princeton, New Jersey–(Newsfile Corp. – September 4, 2026) – CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, is pleased to announce its participation at the upcoming Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9-10, ... CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
CytoSorbents Announces Reverse Stock Split
Reverse Stock Split Previously Approved by Shareholders; Intended to Support Compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement Expected to Become Effective and Trade on Split-Adjusted Basis at the Market Open on September 8, 2026 PRINCETON, N.J., Sept. 3, 2026 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care ... CytoSorbents Announces Reverse Stock Split
